(0.33%) 5 117.01 points
(0.33%) 38 365 points
(0.38%) 15 988 points
(-0.98%) $83.03
(5.56%) $2.03
(0.34%) $2 355.20
(0.49%) $27.67
(4.07%) $959.65
(-0.26%) $0.932
(-0.41%) $10.98
(-0.58%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders...
Stats | |
---|---|
本日の出来高 | 1.06M |
平均出来高 | 214 738 |
時価総額 | 123.37M |
EPS | $0 ( 2024-03-12 ) |
次の収益日 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.933 |
ATR14 | $0.143 (2.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-25 | Trask Anna | Sell | 106 864 | Common Stock |
2023-09-25 | Trask Anna | Sell | 45 000 | Stock Option (right to buy) |
2023-09-25 | Trask Anna | Sell | 52 500 | Stock Option (right to buy) |
2023-09-25 | Trask Anna | Sell | 137 302 | Stock Option (right to buy) |
2023-09-25 | Carson William H. | Sell | 5 000 | Common Stock |
INSIDER POWER |
---|
-72.47 |
Last 92 transactions |
Buy: 13 490 376 | Sell: 25 219 441 |
ボリューム 相関
Decibel Therapeutics, 相関
10 最も正の相関 | |
---|---|
BYFC | 0.916 |
BOOM | 0.915 |
MDXG | 0.906 |
ASLE | 0.893 |
CIGI | 0.893 |
SLMBP | 0.89 |
MBIN | 0.888 |
SNPO | 0.887 |
NEXT | 0.885 |
AIRS | 0.883 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Decibel Therapeutics, 相関 - 通貨/商品
Decibel Therapeutics, 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.52 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-2.52 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.08 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.701 |
Financial Reports:
No articles found.
Decibel Therapeutics,
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。